Triazavirin Is Russia's Answer To Flu Viruses
06.11.2009 — News
THE SVERDLOVSK OBLAST.
The new antiviral drug Triazavirin will be offered on sale in Russia in May 2010. Urals scientists have spent 17 years developing this drug.
In the middle of November the drug will be tested at the Science and Research Institute of Influenza of RAMS (Saint Petersburg) on 114 volunteers who contracted the flu, including that of the type A/H1N1. At the first stage of the clinical trials on healthy persons Triazavirin has been proved to be safe, this drug is a representative of a new class of antivirals.
In February 2010 the study results will be transferred to the Federal Service for the Supervision in the Sphere of Healthcare. After this the manufacturer, Unona Holding Ltd. is counting on obtaining the registration certificate for Triazavirin. Batch production of the drug will start at the Medsintez plant in Novouralsk next May-June. The 20 capsule pack that would be enough for a course of treatment will cost 500-700 roubles.
Unona Holding Ltd. informed RusBusinessNews that in the future Triazavirin might come to markets abroad. Slovakian partners, for instance, might undertake the promotion of the drug in the European Union.
|Regions||Project participants||Investment projects||Consulates and Trade Offices||News and Analysis||About the Project|
© RusBusinessNews, 2009.
All rights reserved.
Establishing a hyperlink to RIA RusBusinessNews is required for using any of the material published on this website.
News and analytical reviews are translated into foreign languages by the TRANSLIT Translation Agency
|«Sum of technologies»®